Alnylam Pharmaceuticals, Inc. (ALNY) — 分析摘要
Alnylam Pharmaceuticals, Inc.（ALNY）的市值为38.46十亿美元，最近一年的营收同比增长了+65.2%。净利润率为8.4%。当前市盈率为122.6倍。
核心要点
- 营收同比变化+65.2%
- 净利润率8.4%
- 市盈率122.6倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，ALNY的营收增长为+65.2%，市盈率为122.6倍。
Alnylam Pharmaceuticals, Inc. (ALNY)
更新 — ET · 来源 POLYGON
红旗与风险提示重点关注
当前存在需要关注的风险信号，应与估值结果一并解读。
利息保障倍数为 2.0x — 应对盈利下滑空间有限
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
2,500
总部
CAMBRIDGE, MA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。